Patents by Inventor Pengcheng Patrick Shao

Pengcheng Patrick Shao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240084304
    Abstract: Provided are a composition and method for inhibiting angiotensinogen (AGT) protein expression. Specifically, provided are a composition and method capable of being used for reducing AGT gene expression and treating AGT-related diseases and disorders. Provided are an AGT dsRNA reagent capable of being used for reducing AGT expression in a cell and an object, an AGT antisense polynucleotide reagent, a composition containing the AGT dsRNA reagent, and a composition containing the AGT antisense polynucleotide reagent.
    Type: Application
    Filed: September 25, 2023
    Publication date: March 14, 2024
    Applicant: Shanghai Argo Biopharmaceutical Co., Ltd.
    Inventors: Dongxu Shu, Pengcheng Patrick Shao
  • Publication number: 20230092615
    Abstract: Compositions and methods useful to reduce expression of methylation-controlled J-protein (MCJ) gene and for treatment of MCJ-associated diseases and conditions are provided. Provided are MCJ dsRNA agents, MCJ antisense polynucleotide agents, compositions comprising MCJ dsRNA agents, and, compositions comprising MCJ antisense polynucleotide agents that can be used to reduce MCJ expression in cells and subjects.
    Type: Application
    Filed: February 20, 2021
    Publication date: March 23, 2023
    Inventors: Pengcheng Patrick Shao, Mercedes Rincon
  • Publication number: 20220273669
    Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 1, 2022
    Applicant: Merck Sharp Dohme Corp.
    Inventors: Qingmei Hong, Jason E. Imbriglio, Angela D. Kerekes, Tanweer Khan, Claire Lankin, Derun Li, Rui Liang, Pengcheng Patrick Shao, Zhicai Wu, Yusheng Xiong, Feng Ye, Hyewon Youm, Yang Yu, Anthappan Tony Kurissery, Venukrishnan Komanduri
  • Publication number: 20220175934
    Abstract: Targeting ligand clusters, and methods of preparing same, are described. A targeting ligand cluster may include first linkers attached to phenolic hydroxyl groups of gallic acid, and one or more targeting ligands attached to each of the first linkers. The targeting ligand cluster may also include a second linker attached to a carboxylic acid of the gallic acid, and at least one of a protecting group, a phosphoramidite, or an oligonucleotide attached to the second linker.
    Type: Application
    Filed: March 19, 2020
    Publication date: June 9, 2022
    Inventor: Pengcheng Patrick SHAO
  • Publication number: 20180230166
    Abstract: The invention provides compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2, D3, X, Y, A1, A2, R1, R5 and the subscript a are as described herein.
    Type: Application
    Filed: July 8, 2016
    Publication date: August 16, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Revathi Reddy Katipally, Petr Vachal, Jayanth Thiruvellore Thatai, Sujit Kumar Sarkar
  • Patent number: 10011572
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Feng Ye, Petr Vachal, Jayanth Thiruvellore Thatal
  • Patent number: 9981970
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is —C(?O) or —S(O)2—, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Pengcheng Patrick Shao, Arto K. Krikorian, Petr Vachal
  • Publication number: 20170210715
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 27, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Feng Ye, Petr Vachal, Jayanth Thiruveliore Thatal
  • Patent number: 9663534
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is (CH2) or O, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 30, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Feng Ye, Petr Vachal
  • Patent number: 9580396
    Abstract: In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): (structurally represented) or tautomers thereof, and pharmaceutically acceptable salts of said compounds, wherein R1, R2, R3, X, Y, s, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 28, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jared N. Cumming, Jack D. Scott, Jr., Andrew W. Stamford, Ulrich Iserloh, Santhosh Francis Neelamkavil, Pengcheng Patrick Shao, Jonathan E. Wilson
  • Publication number: 20160318950
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is (CH2) or O, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:
    Type: Application
    Filed: December 12, 2014
    Publication date: November 3, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick SHAO, Feng YE, Petr VACHAL
  • Publication number: 20160264538
    Abstract: In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): (structurally represented) or tautomers thereof, and pharmaceutically acceptable salts of said compounds, wherein R1, R2, R3, X, Y, s, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto.
    Type: Application
    Filed: December 16, 2013
    Publication date: September 15, 2016
    Inventors: Jared N. Cumming, Jack D. Scott, JR., Andrew W. Stamford, Ulrich Iserloh, Santhosh Francis Neelamkavil, Pengcheng Patrick Shao, Jonathan E. Wilson
  • Patent number: 9376408
    Abstract: Thiazolidinone compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 28, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Revathi Reddy Katipally
  • Patent number: 9346825
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: May 24, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Wanying Sun, Revathi Reddy Katipally, Petr Vachal, Feng Ye, Jian Liu, Deyou Sha
  • Publication number: 20150307464
    Abstract: Thiazolidinone compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Application
    Filed: December 17, 2013
    Publication date: October 29, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Revathi Reddy Katipally
  • Publication number: 20140378493
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Pengcheng Patrick Shao, Wanying Sun, Revathi Reddy Katipally, Petr Vachal, Feng Ye, Jian Liu, Deyou Sha
  • Patent number: 8871738
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: October 28, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pengcheng Patrick Shao, Wanying Sun, Revathi Reddy Katipally, Petr Vachal, Feng Ye, Jian Liu, Deyou Sha
  • Publication number: 20130109649
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Application
    Filed: October 25, 2012
    Publication date: May 2, 2013
    Inventors: Pengcheng Patrick Shao, Wanying Sun, Revathi Reddy Katipally, Petr Vachal, Feng Ye, Jian Liu, Deyou Sha
  • Patent number: 8304434
    Abstract: A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: November 6, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Prasun K. Chakravarty, Yanbing Ding, Joseph L. Duffy, Hassan Pajouhesh, Pengcheng Patrick Shao, Sriram Tyagarajan, Feng Ye
  • Publication number: 20110172223
    Abstract: A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: September 21, 2009
    Publication date: July 14, 2011
    Inventors: Prasun K. Chakravarty, Pengcheng Patrick Shao